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A Rnd3/p190RhoGAP pathway regulates RhoA 
activity in idiopathic pulmonary fibrosis 
fibroblasts
ABSTRACT Idiopathic pulmonary fibrosis (IPF) is an incurable disease of the lung that is char-
acterized by excessive deposition of extracellular matrix (ECM), resulting in disruption of 
normal lung function. The signals regulating fibrosis include both transforming growth factor 
beta (TGF-β) and tissue rigidity and a major signaling pathway implicated in fibrosis involves 
activation of the GTPase RhoA. During studies exploring how elevated RhoA activity is sus-
tained in IPF, we discovered that not only is RhoA activated by profibrotic stimuli but also that 
the expression of Rnd3, a major antagonist of RhoA activity, and the activity of p190RhoGAP 
(p190), a Rnd3 effector, are both suppressed in IPF fibroblasts. Restoration of Rnd3 levels in 
IPF fibroblasts results in an increase in p190 activity, a decrease in RhoA activity and a decrease 
in the overall fibrotic phenotype. We also find that treatment with IPF drugs nintedanib and 
pirfenidone decreases the fibrotic phenotype and RhoA activity through up-regulation of 
Rnd3 expression and p190 activity. These data provide evidence for a pathway in IPF where 
fibroblasts down-regulate Rnd3 levels and p190 activity to enhance RhoA activity and drive 
the fibrotic phenotype.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progressive lethal lung dis-
ease of unknown cause. In the United States, IPF affects 150,000–
200,000 people and causes 40,000 deaths per year (Raghu et al., 
2014). The disease is characterized by patchy fibrotic areas with per-
sistent fibroblast and myofibroblast proliferation and excess deposi-
tion of extracellular matrix (ECM) that results in a permanent distor-
tion of lung architecture and a progressive irreversible loss of lung 
function (King, Jr. et al., 2001).
IPF is categorized as a fibroproliferative disorder characterized by 
an aberrant wound healing response (Raghu et al., 2011). Myofibro-
blasts function transiently during wound healing where they deposit 
and remodel ECM and exert mechanical tension to restore tissue in-
tegrity (Gabbiani et al., 1971; Tomasek et al., 2002). Myofibroblast 
function is temporally and spatially regulated in normal acute wounds 
but not in pathogenic fibrotic conditions. The persistence of myofi-
broblasts, long past when they are needed, is a well-established fea-
ture of fibrosis. These cells are key effectors in IPF, and targeting 
myofibroblasts is an important therapeutic option (Eickelberg and 
Laurent, 2010). Although the precise mechanism through which the 
persistent myofibroblast phenotype is acquired remains unclear, 
transforming growth factor beta (TGF-β) and mechanical stiffness 
have been identified as key factors (Vaughan et al., 2000; Hinz, 2010).
The mechanical properties of the fibrotic lung play a pivotal role 
in regulating the fibrotic phenotype. The excess ECM deposition 
observed during IPF results in the production of stiff scar tissue that 
obstructs normal lung function (Hinz, 2015). Substrates with the en-
hanced stiffness of fibrotic tissues have been shown to drive healthy 
cells toward a fibrogenic phenotype (Hinz, 2010; Saums et al., 2014). 
Conversely, softer substrates that mimic normal tissue stiffness can 
suppress the fibrotic phenotype in a number of cell types, including 
lung fibroblasts (Balestrini et al., 2012).
TGF-β is the most potent profibrotic cytokine known and the main 
chemical factor in myofibroblast differentiation (Hinz et al., 2007). 
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Interestingly, a mechanical mechanism of TGF-β activation has been 
described whereby integrin contractile forces on the matrix release 
active TGF-β (Wipff et al., 2007; Wipff and Hinz, 2008). These findings 
suggest a model where the combination of TGF-β and matrix stiff-
ness could engage in a feed forward signaling loop (Marinkovic et al., 
2012). The enhanced ECM deposition by the myofibroblasts leads to 
the production of a stiffer matrix with a higher mechanical load when 
compared with healthy ECM produced by fibroblasts (Klingberg 
et al., 2014). This mechanically stiffer ECM, in turn, leads to more ef-
ficient activation of TGF-β, and the increased levels of TGF-β further 
enhance myofibroblast differentiation leading to positive feedback 
that sustains the profibrotic environment of the lung. Conversely, 
healthy fibroblasts produce softer matrices which fail to promote 
TGF-β activation, prevent the feed-forward loop, and maintain the 
compliant lung matrix (Marinkovic et al., 2012). It seems then that the 
combination of both the chemical and mechanical signals provide 
linked cues to drive cells into a disease state (Shimbori et al., 2013).
While there is strong evidence to suggest that the intersection of 
TGF-β and mechanical signaling pathways are key regulators of the 
IPF phenotype, there is still a major gap in understanding the signal-
ing events that occur downstream of these pathways. Interestingly, 
the TGF-β and mechanical signals seem to converge on RhoA, a key 
regulator of cell contractility and the actin cytoskeleton (Amano 
et al., 1996; Chrzanowska-Wodnicka and Burridge, 1996; Kimura 
et al., 1996). Fibroblasts are known to activate RhoA in response to 
a number of mechanical stimuli (Lessey et al., 2012) and in response 
to TGF-β stimulation (Vardouli et al., 2005; Johnson et al., 2014). 
Rho GTPases act as molecular switches, active when GTP-bound 
and inactive when GDP-bound. Guanine nucleotide exchange fac-
tors (GEFs) activate Rho proteins by catalyzing the exchange of GDP 
for GTP, whereas GTPase activating proteins (GAPs) stimulate the 
intrinsic GTPase activity of Rho proteins, rendering them inactive 
(Schmidt and Hall, 2002; Jaffe and Hall, 2005). A recent study 
demonstrated that inhibition of Rho-associated protein kinase/Rho-
associated, coiled-coil–containing protein kinase (ROCK) signaling 
(a known downstream effector of RhoA) decreases fibrosis in a 
mouse model of IPF (Jiang et al., 2012; Bei et al., 2013; Zhou et al., 
2013), further suggesting that the RhoA pathway may regulate IPF.
In this study, we seek to determine how RhoA is regulated down-
stream of mechanical and TGF-β signaling. Determining the path-
ways that regulate Rho proteins in IPF should provide enhanced 
understanding of the molecular mechanisms underlying this disease 
and may identify potential therapeutic targets.
RESULTS
RhoA activity drives the IPF phenotype
Previous work has demonstrated that RhoA/ROCK signaling is up-
regulated in IPF fibroblasts (Jiang et al., 2012; Bei et al., 2013; Zhou 
et al., 2013). However, little is known about the upstream regulators 
of RhoA activity in IPF. Because upstream regulators may provide po-
tential therapeutic targets, we investigated the molecular mecha-
nisms that regulate RhoA signaling in IPF cell lines. Comparing two 
IPF fibroblast lines (LL29 and LL97a) with normal pulmonary fibro-
blasts (MRC5) revealed elevated expression of FN and collagen I, as 
well as expression of smooth muscle actin (SMA), a marker for myofi-
broblast differentiation (Darby et al., 1990) (Figure 1A). These data 
recapitulate the IPF fibroblast phenotype observed in patients (Kuhn 
and McDonald, 1991). RhoA activity was enhanced in the two IPF cell 
lines compared with the normal fibroblasts (Figure 1, B and C). To 
determine whether the fibrosis phenotype of elevated FN, collagen, 
and SMA is dependent on RhoA activity, we used an adenovirally 
delivered RhoA microRNA (miRNA) to knock down RhoA expression 
in the LL29 and LL97a IPF cell lines and a myc-tagged RhoA construct 
(RhoA-NT) with five silent mutations within the RNA interference 
(RNAi) targeting sequence, thus allowing reexpression. These con-
structs were validated in an earlier publication (Aghajanian et al., 
2009). We found that knocking down RhoA expression decreased FN, 
collagen, and SMA levels while reexpression of RhoA with the RhoA-
NT restored with IPF phenotype (Figure 1D), consistent with the idea 
that RhoA activity is critical in driving the fibrosis phenotype.
Rnd3/p190 regulate RhoA activity in IPF
As we continued our analysis comparing the IPF fibroblasts with nor-
mal lung fibroblasts, we evaluated the expression levels of the Rnd 
family of Rho proteins (Figure 2). Rnd1 was expressed at equal levels 
in the IPF and normal lung fibroblasts, and no detectable levels of 
Rnd2 were observed in any of the cell lines. However, examination 
of lysates prepared from testis, a tissue known to express Rnd2 
(Nobes et al., 1998), did show successful antibody detection of Rnd2 
(Supplemental Figure S1). Rnd3, however, showed decreased ex-
pression in the IPF cells when compared with their normal counter-
part (Figure 2, A and B). Interestingly, Rnd3 is known to be antago-
nistic to RhoA signaling through activation of p190RhoGAP (p190) 
(Wennerberg et al., 2003). To determine whether p190 activity was 
FIGURE 1: RhoA is required for the IPF phenotype. (A) MRC5, LL29, 
and LL97a cell lysates were analyzed by Western blotting for FN, 
collagen I, SMA, and Erk2 (as a loading control). (B) MRC5, LL29, and 
LL97a cells were lysed, and active RhoA was precipitated from lysates 
using GST-RBD and immunoblotted with RhoA antibodies. 
(C) Quantification of RhoA activity in three independent assays. 
p < 0.05 vs. MRC5 as determined by a t test. (D) LL29 and LL97a cells 
were infected with an adenoviral miRNA against RhoA for 48 h to 
knock down RhoA expression. Cell lysates were analyzed by Western 
blot for expression of RhoA, FN, collagen I, SMA, and Erk2. (D) LL29 
and LL97a cells were infected with RhoA miRNA-encoding adenovirus 
or a control adenovirus for 48 h. After 48 h, cells were transfected 
with a myc-RhoA NT construct for 24 h, where indicated. After a total 
of 72 h, total cell lysates were analyzed by Western blot for FN, 
collagen, SMA, Erk2, and RhoA expression. Note that the position of 
the myc-RhoA NT construct was detected higher in the blot than the 
endogenous RhoA.
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MRC5, LL29, and LL97a cells and the precipitates were examined for 
the presence of Rnd3. MRC5 cells showed a greater interaction be-
tween p190 and Rnd3 (Figure 2E), consistent with the enhanced ac-
tivity of p190 observed in the MRC5 cells.
The reciprocal relationship between RhoA activity and Rnd3 ex-
pression/p190 activity is interesting, but we wanted to determine 
whether Rnd3 was regulating RhoA activity via its activation of p190. 
To address this relationship, Rnd3 was exogenously expressed in 
LL29 IPF cells. Rnd3 overexpression in IPF cells increased p190 activ-
ity (Figure 2, F and H) and decreased RhoA activity (Figure 2, F and 
G). Additionally, enhanced expression of Rnd3 in the LL29 cells de-
creased the expression of FN, collagen, and SMA (Figure 2I). To ex-
plore the morphological consequences of Rnd3 overexpression in 
IPF cells we examined stress fiber formation, as it is a well-character-
ized readout of RhoA activity (Ridley and Hall, 1992). LL29 IPF cells 
and LL29 cells transfected with Rnd3 were plated onto fibronectin-
coated coverslipts for 24 h. The cells were then fixed and F-actin vi-
sualized with a Texas-red-labeled phalloidin (Supplemental Figure 
S2). The LL29 cells transfected with Rnd3 showed less prominent 
stress fibers and an overall cell rounding. This is in agreement with 
earlier studies in Cos7 cells, demonstrating that Rnd3 overexpression 
results in stress fiber collapse and cell rounding (Wennerberg et al., 
2003). Taken together, these data suggest that the decreased levels 
of Rnd3 in the IPF cells result in decreased p190 activity, causing in-
creased RhoA activity. Furthermore, these results indicate that Rnd3 
control of RhoA signaling is a key regulator of the IPF phenotype.
Loss of Rnd3 drives the fibrotic phenotype
We asked whether decreasing Rnd3 levels in normal pulmonary fi-
broblasts would drive a more fibrotic phenotype in these cells. 
Using two different small interfering RNAs (siRNAs) against Rnd3 
(Rnd3 #1 and Rnd3 #2) to knock down Rnd3 expression in MRC5 
cells (Figure 3A), we observed that knockdown of Rnd3 caused a 
decrease in p190 activity (Figure 3, B and C), an increase in RhoA 
activity (Figure 3, D and E), and an increase in the expression of FN, 
collagen, and SMA (Figure 3F). These data demonstrate that de-
pression of Rnd3 drives a more fibrotic phenotype in normal lung 
fibroblasts.
TGF-β signals through the Rnd3/p190/RhoA pathway
TGF-β has been implicated in IPF, and TGF-β signaling is known to 
activate RhoA in a number of cell types (Bhowmick et al., 2001; 
Shen et al., 2001; Edlund et al., 2002; Chen et al., 2006). We sought 
to determine whether TGF-β regulated the Rnd3/p190/RhoA path-
way in IPF. As patients with IPF show enhanced levels of TGF-β, we 
compared levels of active TGF-β present in cell culture superna-
tants between the IPF fibroblasts and normal lung fibroblasts. 
Supernatants from MRC5, LL29, and LL97a cultures were assayed 
for active TGF-β by enzyme-linked immunosorbent assay (ELISA). 
Active TGF-β levels were approximately fourfold higher in the con-
ditioned media of the IPF cell lines LL29 and LL97a compared with 
the conditioned media from the MRC5 normal lung fibroblasts 
(Figure 4A). To test whether TGF-β applied to normal lung fibro-
blasts promotes a more IPF-like phenotype, MRC5 cells were 
treated with TGF-β and Western blot analysis was performed to 
determine the expression of the IPF phenotype markers. MRC5 
cells treated with TGF-β elevated the levels of FN, collagen, and 
SMA (Figure 4B). TGF-β treatment enhanced RhoA activity in the 
MRC5 cells (Figure 4, C and D). Further analysis revealed that TGF-β 
treatment resulted in decreased p190 activity (Figure 4, E and F) 
and decreased Rnd3 levels (Figure 4, G and H), while levels of Rnd1 
remain unaffected and Rnd2 remains unexpressed (Figure 4G).
FIGURE 2: Rnd3 and p190 regulate RhoA activity in IPF cells. 
(A) MRC5, LL29, and LL97a cell lysates were analyzed by Western 
blotting for Rnd1, Rnd2, Rnd3, and Erk2 (loading control). 
(B) Quantification of Rnd3 expression from three independent assays. 
p < 0.05 vs. MRC5 as determined by a t test. (C) MRC5, LL29, and 
LL97a cells were lysed and activation of p190 was determined using 
the GST-RhoAQ63L pull-down assay and immunoblotting with p190 
antibodies. (D) Quantification of p190 activity from three independent 
assays. p < 0.05 vs. MRC5 as determined by a t test. (E) MRC5, LL29, 
and LL97a cells were lysed in immunoprecipitation buffer and p190 
was immunoprecipitated from the cell lysates. Immunoprecipitates 
were then blotted for the presence of Rnd3. (F) LL29 cells were 
transfected with Rnd3 cDNA. Cell lysates were then analyzed for 
RhoA activity through a GST-RBD pull-down assay and p190 activity 
through a GST-RhoAQ63L pull-down assay. Western blot analysis of pull 
downs and total cell lysates were analyzed for levels of Rnd3, RhoA, 
and p190. (G, H) Quantification of RhoA activity (G) and p190 activity 
(H) from three independent assays. *p < 0.05 vs. (–) Rnd3 as 
determined by a t test. (I) LL29 cells were transfected with Rnd3 
cDNA. Cell lysates were subjected to Western blot analysis for FN, 
collagen I, and SMA, as well as Erk2 (loading control).
altered in the IPF cells compared with the normal lung fibroblasts, 
we used a constitutively active RhoA pull-down assay (Garcia-Mata 
et al., 2006). Western blot analysis of active GAPs pulled down from 
MRC5, LL29, and LL97a cell lysates revealed that p190 activity was 
depressed in the IPF fibroblasts, LL29 and LL97a, when compared 
with the normal lung fibroblast line, MRC5 (Figure 2, C and D). To 
examine the interaction between p190 and Rnd3, coimmunopre-
cipitation analysis was performed. P190 was precipitated from 
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D and E) and a decrease in RhoA activity in IPF cells treated with 
SB431542 (Figure 5, F and G). TGF-β signaling occurs through both 
Smad-dependent and Smad-independent pathways (Zhang, 2009). 
To determine whether the changes observed in Rnd3 expression 
were Smad dependent, we treated the LL29 IPF cells with the Smad3 
inhibitor, SIS3, and measured Rnd3 expression by Western blot. We 
found no change in Rnd3 levels on SIS3 treatment, indicating that the 
TGF-β signaling regulating Rnd3 expression in IPF cells is Smad inde-
pendent (Figure 5H).
We reasoned that inhibition of TGF-β signaling may prevent the 
IPF cell–conditioned media from promoting an IPF-like phenotype 
in the normal lung cells. To test this, we incubated MRC5 cells with 
IPF cell–conditioned media (from the LL29 and LL97a cells) in the 
presence or absence of the TGF-β receptor inhibitor, SB431542. 
MRC5 cells treated with the SB inhibitor greatly abrogated the ef-
fects of the IPF cell–conditioned media. MRC5 cells in the presence 
of SB431542 showed higher levels of Rnd3 than control cells when 
treated with IPF cell–conditioned media (Supplemental Figure S4, A 
and B). Likewise, the cells treated with SB431542 showed higher 
levels of p190 activity than control cells in the presence of IPF-con-
ditioned media (Supplemental Figure S4, C and D). Finally, RhoA 
activity levels were decreased by SB431542 relative to control 
FIGURE 4: TGF-β induces the IPF phenotype. (A) Conditioned 
medium was collected from MRC5, LL29, and LL97a cells and assayed 
for active TGF-β present in the supernatant by ELISA. (B) MRC5 cells 
were treated with 10 ng/ml TGF-β for 24 h. Cells were lysed, and 
lysates were evaluated by Western blot for FN, collagen I, SMA, and 
Erk2. (C) MRC5 cells were treated with 10 ng/ml TGF-β for 24 h. Cells 
were lysed, and active RhoA was precipitated from lysates using 
GST-RBD and immunoblotted with RhoA antibodies. (D) Quantification 
of RhoA activity from three independent assays. (E) MRC5 cells were 
treated with 10 ng/ml TGF-β for 24 h. Cells were lysed, and p190 GAP 
activity was assessed through a GST-RhoAQ63L pull-down assay. 
(F) Quantification of p190 GAP activity from three independent 
assays. (G) MRC5 cells were treated with 10 ng/ml TGF-β for 24 h. 
Cells were lysed, and lysates were evaluated by Western blot with 
antibodies against Rnd3, Rnd2, and Rnd1. (H) Quantification of Rnd3 
expression in three independent assays. *p < 0.05 vs. (–)TGF-β as 
determined by a t test.
As TGF-β promoted the IPF phenotype, we hypothesized that 
treatment of MRC5 cells with IPF-conditioned media would also in-
duce the Rho-dependent IPF phenotype. To test this hypothesis, we 
incubated MRC5 cells with conditioned medium from IPF cells LL29 
and LL97a or from normal MRC5 cells. We then examined the Rnd3/
p190/RhoA signaling pathway in the MRC5 cells treated with these 
conditioned media. MRC5 cells incubated with IPF-conditioned me-
dia (from the LL29 and LL97a cells) displayed a decrease in both 
Rnd3 levels (Supplemental Figure S3, A and B) and p190 activity 
(Supplemental Figure S3, C and D), as well as a concomitant in-
crease in RhoA activity (Supplemental Figure S3, E and F). To further 
analyze the effects of IPF cell–conditioned media on normal MRC5 
lung cells, the IPF phenotype markers were examined by Western 
blot. Treatment of normal lung cells with IPF cell–conditioned media 
enhanced the expression of the IPF markers FN, collagen, and SMA 
(Supplemental Figure S3G).
The role for TGF-β signaling in regulating the IPF phenotype 
through the Rnd3/p190/RhoA pathway was further investigated us-
ing SB431542 to inhibit TGF-β receptor signaling (Laping et al., 
2002). IPF cells LL29 and LL97a were treated with SB431542, and 
expression of the IPF phenotype markers was assessed. Inhibition of 
TGF-β signaling with SB431542 caused a decrease in the expres-
sion of FN, collagen, and SMA in the IPF cell lines (Figure 5A). To 
determine whether the inhibition of TGF-β signaling was affecting 
the IPF phenotype through alterations in the Rnd3/p190/RhoA path-
way, we examined the level of Rnd3 expression and the activities of 
p190 and RhoA. SB431542 increased the levels of Rnd3 in IPF cells, 
while levels of Rnd1 remained unchanged and levels of Rnd2 re-
mained undetectable (Figure 5, B and C). Along with the increased 
Rnd3 expression, we observed an increase in p190 activity (Figure 5, 
FIGURE 3: Rnd3 knockdown enhances the fibrotic phenotype in 
normal lung fibroblasts. MRC5 cells were transfected with control, 
Rnd3 #1, or Rnd3 #2 siRNA for 72 h. (A) Cell lysates were analyzed by 
Western blotting for Rnd3 and Erk2 (loading control). (B) Cell lysates 
were analyzed for p190 activity through a GST-RhoAQ63L pull-down 
assay. (C) Quantification of p190 activity from three independent 
assays. (D) Cell lysates were analyzed for RhoA activity through a 
GST-RBD pull-down assay. (E) Quantification of RhoA activity from 
three independent assays. (F) Total cell lysates were analyzed by 
Western blot for expression of FN, collagen I, SMA, and Erk2 (loading 
control). *p < 0.05 vs control as determined by a t test.
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treated cells (Supplemental Figure S4, E and F). We also wanted to 
determine whether TGF-β signaling was necessary to drive the IPF-
like phenotype in normal lung cells treated with IPF cell–conditioned 
media. Indeed, we found that in response to IPF-conditioned me-
dia, SB431542-treated cells showed reduced levels of FN, collagen, 
and SMA when compared with control cells treated with the same 
IPF-conditioned media (Supplemental Figure S4G). Collectively, 
these results suggest that TGF-β is a strong upstream regulator of 
the Rnd3/p190/RhoA pathway in IPF fibroblasts and confirm the 
role of TGF-β as a major cytokine driving the IPF phenotype.
Our data demonstrate that TGF-β signaling can affect Rnd3 lev-
els. We have also shown that alterations in Rnd3 expression regulate 
the IPF phenotype. To determine whether TGF-β signaling mediates 
the IPF phenotype through modulation of Rnd3 levels, Rnd3 was 
overexpressed in LL29 cells, and then these cells were treated with 
TGF-β or with SB431542 to stimulate or inhibit the TGF-β pathway, 
respectively. Overexpression of Rnd3 rendered the IPF phenotype 
unresponsive to changes in TGF-β signaling (Figure 6A). In earlier 
work (Figure 3), we showed that knockdown of Rnd3 expression in-
duced the IPF phenotype. Just as driving Rnd3 expression in MRC5 
cells inhibited this response to TGF-β, we asked whether removal of 
Rnd3 would similarly block the response of MRC5 cells to TGF-β. To 
examine this possibility, Rnd3 expression was knocked down in the 
MRC5 cells using siRNA, and the IPF phenotype measured in re-
sponse to TGF-β and SB431542. Rnd3 knockdown rendered the 
cells unable to regulate the IPF phenotype in response to alterations 
in TGF-β signaling (Figure 6B). Collectively, these data suggests that 
TGF-β regulation of the IPF phenotype requires the modulation of 
Rnd3 levels.
Mechanical stiffness modulates Rnd3/p190/RhoA signaling
One of the hallmarks of IPF is the increased stiffness of the lung 
that occurs as the disease progresses. Normal lung tissue has a 
stiffness of approximately 2 kPa, while fibrotic lung tissue can 
show an increase in stiffness to approximately 20 kPa (Liu et al., 
2010; Booth et al., 2012). To mimic the progression of stiffness 
observed during IPF, cells were cultured on substrates of 2, 8, and 
25 kPa. Plating these cells on substrata of increasing stiffness in-
creased the levels of TGF-β produced by the cells (Figure 7A), 
consistent with previous findings (Wipff et al., 2007). As we earlier 
determined that TGF-β regulates RhoA GTPase signaling in IPF 
cells, we sought to determine whether changes in substrate 
stiffness also regulate RhoA activity. The IPF fibroblasts showed 
FIGURE 5: TGF-β signaling regulates the RhoA signaling pathway 
in IPF. Cells were treated, with or without 10 µM of the TGF-β 
receptor inhibitor SB431542 for 24 h. (A) LL29 and LL97a cells were 
lysed and levels of FN, collagen I, SMA, and Erk2 were assessed by 
Western blot. (B) LL29 and LL97a lysates were analyzed for 
expression of Rnd3, Rnd2, Rnd1, and Erk2 (loading control). 
(C) Quantification of Rnd3 expression from three independent 
experiments. (D) LL29 and LL97a cells were then analyzed for p190 
activity using a GST-RhoAQ63L pull-down assay. (E) Quantification of 
p190 activity from three independent assays. (F) LL29 and LL97a 
lysates were then analyzed for the activation of RhoA measured 
through a GST-RBD pull-down assay as described under Materials 
and Methods. (G) Quantification of RhoA activity from three 
independent assays. (H) Cells were treated with or without the 
SMAD3 inhibitor SIS3 at a concentration of 10 µM for 24 h. Cells 
were then lysed and Rnd3 levels were evaluated by Western blot. 
*p < 0.05 vs. control (–) SB431542 cells as determined by a t test.
FIGURE 6: TGF-β regulation of the IPF phenotype requires 
modulation of Rnd3 levels. (A) LL29 cells were transfected with 
GST-Rnd3 cDNA to yield LL29 Rnd3 overexpressing cells. Cells were 
then treated with 10 ng/ml TGF-β or 10 µM SB431542. Cells were 
lysed, and lysates evaluated for the expression of FN, collagen I, SMA, 
Erk2 (loading control), and Rnd3. (B) MRC5 cells were transfected with 
Rnd3 #1 siRNA for 72 h and then treated with 10 ng/ml TGF-β or 10 
uM SB431542. Cells were lysed, and lysates evaluated for the 
expression of FN, collagen I, SMA, Erk2 (loading control), and Rnd3.
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higher levels of RhoA activity and concomitant lower levels of 
Rnd3 and p190 activity on stiffer substrates when compared with 
less stiff substrates (Figure 7, B–G). Analysis of the IPF phenotype 
across enhanced substrate rigidities revealed a stiffness-depen-
dent increase in FN, collagen, and SMA (Figure 7H). These data 
are consistent with earlier studies demonstrating that enhanced 
substrate stiffness exacerbates the signaling pathways that regu-
late the IPF phenotype (Hinz, 2012).
Is the effect of substratum stiffness mediated by effects 
on TGF-β?
Having demonstrated that Rnd3 expression is a critical regulator 
of the IPF phenotype, we wanted to examine the relationship 
between Rnd3 expression, TGF-β signaling, and substrate stiffness 
in more detail. To determine whether the change in substrate stiff-
ness was critical in regulating Rnd3 expression levels or whether the 
effects of stiffness were mediated by enhanced TGF-β signaling, we 
plated LL29 cells on substrates of increasing stiffness and inhibited 
TGF-β signaling with SB431542. Analysis of Rnd3 levels showed that 
the IPF cells decreased their expression of Rnd3 both in the pres-
ence of TGF-β signaling, as well as in the absence of TGF-β signal-
ing (after SB431542 treatment) (Figure 7I). These data indicate that 
alterations in substrate stiffness are sufficient to drive changes in 
Rnd3 levels in IPF cells, greater stiffness leading to lower levels of 
Rnd3 expression regardless of the presence or absence of TGF-β 
signaling.
To examine whether increasing substrate stiffness would be 
sufficient to initiate the fibrotic phenotype in the MRC5 normal 
lung fibroblasts, MRC5 cells were plated on increasing substrate 
rigidities (2, 8, and 25 kPa) and the IPF phenotype markers mea-
sured (Figure 7J). Increasing substrate stiffness increased the de-
position of FN and collagen but was insufficient to induce expres-
sion of SMA. This result is consistent with our earlier results 
demonstrating that MRC5 cells require TGF-β treatment even 
when plated on an extremely stiff substrate (plastic) to induce 
SMA expression (Figure 4B).
Exogenous expression of Rnd3 inhibits stiffness-enhanced 
expression of fibronectin, collagen, and SMA
Our data suggest that decreased expression of Rnd3 drives en-
hanced RhoA signaling and leads to a more fibrotic phenotype in 
IPF. These data also suggest that Rnd3 expression is responsive to 
substrate stiffness, with stiffer substrates showing lower levels of 
Rnd3. To determine whether the enhanced fibrotic phenotype 
seen on stiffer substrates requires modulation of Rnd3 levels, Rnd3 
was exogenously expressed in the LL29 IPF cells. The cells were 
plated on substrates of increasing rigidity (Figure 8A). Cells ex-
pressing Rnd3 exogenously were no longer able to decrease p190 
activity in response to increased substrate stiffness (Figure 8B). In 
addition, cells expressing Rnd3 no longer showed increasing RhoA 
activity with increased substrate stiffness (Figure 8C). The exoge-
nous expression of Rnd3 in the IPF cells abrogated the expression 
of FN, collagen, and SMA in response to enhanced substrate stiff-
ness (Figure 8D).
Nintedanib and pirfenidone impact the Rnd3/p190/RhoA 
pathway
In 2014, pirfenidone and nintedanib were approved in the United 
States to treat IPF. Nintedanib is a tyrosine kinase inhibitor (Hilberg 
et al., 2008), whereas pirfenidone is a drug of unknown mechanism 
FIGURE 7: Increasing substrate rigidity enhances the RhoA signaling 
pathway and IPF phenotype. LL29 cells were cultured on substrates 
of different rigidities: 2, 8, and 25kPa. (A) Conditioned medium was 
collected from LL29 cells and assayed for active TGF-β by ELISA. 
(B) LL29 cells were then lysed and Rnd1, Rnd2, andRnd3 levels 
analyzed by Western blot. (C) Quantification of Rnd3 expression from 
three independent assays. (D) LL29 cells were then analyzed for p190 
activity using a GST-RhoAQ63L pull-down assay. (E) Quantification of 
p190 activity from three independent assays. (F) LL29 lysates were 
then analyzed for the activation of RhoA measured through a 
GST-RBD pull-down assay as described under Materials and Methods. 
(G) Quantification of RhoA activity from three independent assays. 
(H) LL29 cells were lysed, and lysates evaluated by Western blot for 
FN, collagen I, SMA, and Erk2 levels. Note these samples were from 
the same experiment as in B and the Erk2 loading control is the same 
blot. (I) Cells were treated with 10 µM SB431542 for 24 h where 
indicated. Cells were lysed and Rnd3 and Erk2 (loading control) 
levels were assessed by Western blot. *p < 0.05 vs. 2 kPa as 
determined by a t test. (J) MRC5 cells were cultured on increasing 
substrate rigidities (2, 8, and 25kPa). Cells were lysed, and lysates 
evaluated by Western blot for FN, collagen I, SMA, and Erk2 levels 
(loading control).
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with anti-fibrotic properties in multiple animal models (Schaefer 
et al., 2011). However, much remains to be discovered about the 
anti-fibrotic actions of these drugs. We treated LL29 IPF cells with 
pirfenidone or nintedanib and examined the Rho signaling path-
way. Pirfenidone elevates Rnd3 expression (Figure 9, A and B), en-
hances p190 activity (Figure 9, C and D), and decreases RhoA ac-
tivity (Figure 9, E and F). Similar results were obtained when IPF 
cells were treated with nintedanib (Figure 9, A–F). Interestingly, 
when we examined the IPF phenotype after pirfenidone or ninte-
danib treatment, we found a reduction in the levels of FN and 
collagen but SMA levels remained high (Figure 9G). This result is 
consistent with the observation that while both drugs are benefi-
cial to a percentage of patients with IPF, either drug only slows the 
progression of disease (Myllarniemi and Kaarteenaho, 2015; Troy 
and Corte, 2016). To examine the morphological consequences of 
nintedanib and pirfenidone treatment on IPF cells, we stained for 
stress fibers. Control LL29 IPF cells showed prominent stress fi-
bers, whereas LL29 cells treated with nintedanib or pirfenidone 
showed decreased cell spreading and decreased stress fiber for-
mation (Figure 9H), consistent with the phenotype observed on 
Rnd3 overexpression.
To test whether the elevation of Rnd3 levels induced by pirfeni-
done and nintedanib is responsible for the ability of these drugs to 
decrease the IPF phenotype, we used siRNA to deplete the ex-
pression of Rnd3 in LL29 IPF cells and examined their response 
following treatment with nintedanib and pirfenidone (Figure 10A). 
Whereas in control cells, treatment with either drug raised p190 
activity and lowered RhoA activity, cells treated with siRNA were 
no longer able to alter p190 or Rho activity (Figure 10, B and C). 
Furthermore, nintedanib and pirfenidone were no longer able to 
impact the IPF phenotype (FN, collagen levels) in the Rnd3 siRNA-
treated cells (Figure 10D). These data suggest that modulation of 
Rnd3 levels is critical to the anti-fibrotic action of nintedanib and 
pirfenidone.
DISCUSSION
Profibrotic stimuli elevate RhoA activity by depressing Rnd3 
expression and p190RhoGAP activity
The patchy fibrotic areas that are the pathological hallmark of IPF 
are characterized by the presence of highly active fibroblasts and 
myofibroblasts. The origin of these myofibroblasts in IPF tissues 
has been controversial. It has been argued that they derive from 
endogenous pulmonary fibroblasts, from the bone marrow, from 
circulating fibrocytes, from pericytes, and from alveolar epithelial 
cells that have undergone epithelial to mesenchymal transition 
FIGURE 8: Rnd3 overexpression abolishes IPF phenotype in response 
to substrate stiffness. LL29 cells were transfected with Rnd3 (where 
indicated). Cells were then plated on substrates with stiffnesses of 2, 
8, and 25 kPa. (A) Cells were lysed and levels of GST-Rnd3 and Erk2 
(loading control) were evaluated by Western blot. (B) Cells were then 
analyzed for p190 activity using a GST-RhoAQ63L pull-down assay. 
(C) Cell lysates were then analyzed for the activation of RhoA 
measured through a GST-RBD pull-down assay. (D) LL29 cells were 
lysed, and lysates evaluated by Western blot for FN, collagen I, SMA, 
and Erk2 levels.
FIGURE 9: Treatment with pirfenidone and nintedanib impacts the 
RhoA signaling pathway in IPF cells. LL29 cells were treated with 
pirfenidone (1 mM) and nintedanib (1 µM) for 24 h. (A) The LL29 cells 
were then lysed, and Rnd3 levels analyzed by Western blot. 
(B) Quantification of Rnd3 expression from three independent assays. 
(C) The LL29 cells were then analyzed for p190 activity using a 
GST-RhoAQ63L pull-down assay. (D) Quantification of p190 activity from 
three independent assays. (E) LL29 lysates were then analyzed for the 
activation of RhoA measured through a GST-RBD pull-down assay as 
described under Materials and Methods. (F) Quantification of RhoA 
activity from three independent assays. (G) LL29 cells were lysed, 
and lysates evaluated by Western blot for FN, collagen I, SMA, and 
Erk2 levels. * p < 0.05 vs. (–) pirfenidone or (–) nintedanib as 
determined by a t test. (H) LL29 cells were plated onto FN-coated 
coverslips for 8 h and subsequently either untreated or treated with 
nintedanib (1 µM) or pirfenidone (1 mM) for an additional 16 h. F-actin 
staining was detected with Texas-red-labeled phalloidin.
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(Rock et al., 2011; Noble et al., 2012; Barkauskas and Noble, 
2014). Regardless of the origin of the myofibroblasts, there is 
broad agreement that these cells are key effectors in IPF and that 
targeting these cells is an important therapeutic option (Eickelberg 
and Laurent, 2010). Although the precise mechanism through 
which the persistent myofibroblast phenotype is acquired remains 
unclear, TGF-β (Vaughan et al., 2000) and mechanical stiffness 
(Hinz, 2010) have been identified as key factors. Here we report 
that in IPF, TGF-β and mechanical stiffness signal through a RhoA 
pathway to regulate the IPF phenotype. Moreover, we find that 
RhoA activity in IPF is regulated via a Rnd3 and p190RhoGAP 
pathway.
At the outset of this work we anticipated that fibroblasts from IPF 
patients would reveal elevated levels of active RhoA. Similarly, on 
the basis of the literature, we expected that fibroblasts responding 
to TGF-β would have higher RhoA activity (Bhowmick et al., 2001; 
Shen et al., 2001; Edlund et al., 2002; Chen et al., 2006). This is in-
deed what we have found. Additionally, we have shown that the fi-
brotic phenotype (increased expression of SMA, collagen, and fibro-
nectin) is decreased by depleting RhoA expression. Our results 
support the idea that elevated RhoA activity is a major factor in IPF 
and are consistent with studies showing that inhibition of RhoA sig-
naling using ROCK inhibitors is beneficial in animal models of IPF 
(Jiang et al., 2012; Bei et al., 2013; Zhou et al., 2013). Our goal has 
been to identify the upstream signaling pathways involved in RhoA 
activation in IPF cells, and we expected to identify the RhoA GEFs 
responsible for this activation. However, our preliminary analysis did 
not reveal major changes in the activity of several prominent GEFs 
that are expressed in these cells. Instead, we discovered that IPF fi-
broblasts express lower levels of Rnd3, a close RhoA family member 
that is antagonistic to RhoA. Rnd3 (also known as RhoE) is an un-
usual member of the Rho protein family because it lacks GTPase 
activity, and no GAPs or GEFs have been found that act on Rnd3 
(Foster et al., 1996; Nobes et al., 1998). In contrast to most Rho 
proteins, Rnd3 appears to bind GTP at all times, and, consequently, 
to be constitutively active. Rnd3 was originally discovered as a pro-
tein, which, when expressed exogenously in fibroblasts, promotes 
disassembly of stress fibers and induces a round (circular) pheno-
type (Guasch et al., 1998; Nobes et al., 1998). It was subsequently 
shown to oppose RhoA signaling both upstream and downstream. 
It binds to and inhibits ROCK (Rho kinase) (Riento et al., 2005), a 
major RhoA downstream effector. However, it also acts upstream of 
RhoA by binding and activating p190RhoGAP (Wennerberg et al., 
2003) leading to the inactive GDP-bound form of RhoA. Addition-
ally, Rnd3 binds to and inhibits the activation of the RhoA GEF Syx 
(Goh and Manser, 2010). Investigating p190RhoGAP, we found that 
it was expressed equally in normal pulmonary and IPF fibroblasts, 
but its activity was significantly lower in the IPF lines, consistent with 
these cells having higher RhoA activity. Overexpressing Rnd3 in IPF 
cells decreased RhoA activity and decreased the IPF phenotype 
(SMA, collagen I, and fibronectin expression).
IPF patients show higher levels of TGF-β in their plasma (Yong 
et al., 2001) and bronchoalveolar lavage fluid (Hiwatari et al., 1997). 
Additionally, TGF-β is overexpressed in the lung tissue of IPF patients 
(Coker et al., 2001; Bergeron et al., 2003). Not only have we con-
firmed that the IPF cells generate higher levels of active TGF-β, but 
also that inhibiting the TGF-β receptor diminishes the IPF pheno-
type. Multiple studies have shown that TGF-β treatment elevates 
RhoA activity (Bhowmick et al., 2001; Shen et al., 2001; Edlund et al., 
2002; Chen et al., 2006). Notably, we have found that TGF-β de-
creases Rnd3 expression and p190RhoGAP activity, whereas inhibit-
ing the TGF-β receptor elevates Rnd3 expression and p190RhoGAP 
activity and decreases RhoA activity. The mechanical properties of 
fibrotic tissues have been known for some time to contribute to the 
pathology of fibrosis. Fibroblasts differentiate into myofibroblasts 
when plated on substrates with an elastic modulus of pathologically 
stiff fibrotic tissue (Balestrini et al., 2012). Furthermore, decellularized 
ECM derived from the fibrotic lung is sufficient to induce fibrotic 
traits in normal lung fibroblasts, including the expression of SMA and 
enhanced levels of collagen deposition (Booth et al., 2012; Parker 
et al., 2014). Exploring whether increasing matrix rigidity may acti-
vate RhoA by depressing Rnd3 levels and p190 activity, we examined 
the expression and activity of these in IPF cells plated on substrata of 
different rigidity. Our results revealed that cells plated on high rigidity 
substrata have low Rnd3 expression, low p190RhoGAP activity, and 
correspondingly elevated RhoA activity. On the more rigid substrata, 
the IPF cells also displayed increased SMA, collagen, and fibronectin 
expression. All of these results point toward the Rnd3/p190 pathway 
being a critical negative regulator of RhoA activity and being a path-
way that is inhibited under profibrotic conditions.
FIGURE 10: Knockdown of Rnd3 decreases IPF fibroblast sensitivity 
to nintedanib and pirfenidone. LL29 cells were transfected with 
control, Rnd3 #1, or Rnd3 #2 siRNA for 72 h and treated with 
nintedanib (1 µM) or pirfenidone (1 mM) for the final 24 h where 
indicated. (A) The LL29 cells were then lysed and Rnd3 levels analyzed 
by Western blot. (B) The LL29 cells were then analyzed for p190 
activity using a GST-RhoAQ63L pull-down assay. (C) LL29 lysates were 
then analyzed for the activation of RhoA measured through a 
GST-RBD pull-down assay. (D) LL29 cells were lysed, and lysates 
evaluated by Western blot for FN, collagen I, SMA, and Erk2 levels.
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Both TGF-β and a rigid matrix decrease Rnd3 expression, re-
sulting in decreased p190RhoGAP activity and increased RhoA 
activity. However, a stiff matrix also contributes to the activation of 
TGF-β (Wipff et al., 2007), leading to the question of whether 
these stimuli of increased rigidity and TGF-β depress Rnd3 levels 
independently or whether the decrease in Rnd3 expression by stiff 
matrix is downstream of TGF-β. To get at this question, we cul-
tured the IPF fibroblasts on substrata of different rigidities in the 
presence and absence of a TGF-β receptor inhibitor. Even in the 
presence of the inhibitor, the stiff matrix decreased Rnd3 levels. 
We conclude that a stiff matrix and TGF-β activate RhoA indepen-
dently. However, in the context of a fibrotic tissue, they will syner-
gize and contribute to increased fibrosis in a positive feed forward 
loop because they both contribute to increased matrix assembly 
and consequent increased tissue stiffness, with elevated RhoA ac-
tivity playing a part in this cycle. Our results also raise the interest-
ing possibility of Rnd3 transcription being regulated by mechano-
responsive elements.
IPF drugs pirfenidone and nintedanib elevate Rnd3 
expression to depress RhoA activity
Currently, there are no effective therapies for IPF, which is typically 
fatal within 2–3 yr of diagnosis. However, in 2014 two drugs, 
pirfenidone and nintedanib, were approved for IPF patients after 
being found to be beneficial although not curative (Myllarniemi 
and Kaarteenaho, 2015; Troy and Corte, 2016). Nintedanib is a 
tyrosine kinase inhibitor that acts on several receptor tyrosine ki-
nases (PDGFR, FGFR, and VEGFR) (Hilberg et al., 2008). Pirfeni-
done is a drug of unknown mechanism with anti-fibrotic properties 
in multiple animal models, including pulmonary, cardiac, renal, 
and hepatic fibrosis (Schaefer et al., 2011). Curious as to their 
mode of action, we investigated their effects on the Rnd3/p190/
RhoA pathway. Strikingly, both drugs elevate Rnd3 expression and 
p190RhoGAP activity and lead to decreased RhoA activity. Inter-
estingly, while both drugs decreased the levels of FN and collagen 
I associated with the IPF cells, neither drug induced a significant 
decrease in SMA levels. The centrality of RhoA signaling to the IPF 
phenotype makes targeting the regulation of RhoA activity through 
the Rnd3/p190 pathway an appealing therapeutic strategy that 
merits further investigation.
Since the discovery that RhoA activity is modulated via Rnd3’s 
activation of p190RhoGAP, this has been an intriguing pathway but 
one in search of both initiating upstream stimuli and physiological 
relevance. Our results identify this pathway as potentially impor-
tant downstream from TGF-β and one that contributes to TGF-β’s 
pathological role in fibrosis. Our finding that nintedanib, a tyrosine 
kinase inhibitor, elevates Rnd3 expression and p190RhoGAP activ-
ity raises the possibility that this pathway may also be inhibited by 
other tyrosine kinases that elevate RhoA activity. We plan to inves-
tigate these potential signaling pathways in future work. RhoA 
activity is negatively regulated by Rnd3 expression levels, but 
changing the level of a protein’s expression is often a relatively 
slow response that depends on rates of transcription/translation as 
well as on its rate of degradation. Consequently, we suspect that 
the Rnd3/p190 pathway is important in regulating the baseline 
level of RhoA activity and in mediating slow changes in this base-
line. In contrast, GEF activity is typically modulated rapidly in re-
sponse to external signals and signaling pathways, resulting in 
more immediate changes in RhoA activity. It will be interesting to 
investigate further the interplay between these different modes of 
regulation and to determine in what other situations RhoA activity 
is controlled by the Rnd3/p190 pathway.
MATERIALS AND METHODS
Antibodies and reagents
The following antibodies were used: anti-FN (Chen et al., 1978); 
anti-collagen I, anti-Erk2 (Santa Cruz Biotechnology); anti-SMA 
(Abcam); anti-RhoA (Cell Signaling), anti-p190RhoGAP (Cell Signal-
ing); anti-Rnd3 (Millipore); anti-Rnd1 (abCam); anti-Rnd2 (abCam); 
anti-myc (Santa Cruz) and horseradish peroxidase (HRP)-conjugated 
anti-mouse and anti-rabbit secondary antibodies (Jackson Immu-
noResearch). IPF drugs pirfenidone (1 mM) (Santa Cruz Biotechnol-
ogy) and nintedanib (1 µM) (Boehringer) were used. All other 
reagents were from Sigma-Aldrich unless otherwise noted.
Cell culture
MRC5, LL29, and LL97a cells were obtained from the American 
Type Culture Collection and grown in high-glucose DMEM supple-
mented with 10% fetal bovine serum (FBS) and antibiotic–antimy-
cotic solution (all from Life Technologies/ThermoFisher Scientific). 
In some experiments cells were treated for 24 h with 10 µM 
SB431452 (Sigma) or 10 ng/ml TGF-β. For substrate rigidity ex-
periments cells were cultured on hydrogels of 2, 8, or 25 kPa 
(Matrigen) for 24 h prior to harvesting.
Knockdown of RhoA using miRNA adenovirus
Adenoviral miRNA constructs against RhoA and RhoA NT were de-
signed as previously described (Aghajanian et al., 2009). Briefly, 
miRNA adenoviral constructs were designed and engineered using 
the BLOCK-iT Pol II miR RNAi expression vector system (Invitrogen) 
according to the manufacturer’s protocol. Double-stranded oligo-
nucleotides were designed to form an engineered pre-miRNA se-
quence structure that targets a conserved region in human, mouse, 
and rat RhoA: 5′TGCTGAAGACTATGAG CAA GCA TGTCGTTTT-
GGCCACTGACT GAC GAC ATGCTCTCATAGTCTT3′ (21–base pair 
antisense target sequence underlined). Synthesized oligonucle-
otides were annealed and ligated into pcDNA 6.2-GW/EmGFP-miR. 
The EmGFP-miRNA cassette was subsequently shuttled through 
pDONR221(Invitrogen) by Gateway BP recombination and then into 
pAd-CMV-Dest Gateway vector by LR recombination. Each con-
struct was sequence verified and virus was produced in 293A pack-
aging cell line with the ViraPower Adenoviral Expression System 
(Invitrogen) using the manufacturer’s recommended protocol. For 
experiments, cells were infected by 48 h incubation with adenovi-
rus-containing media.
Transfection
The generation of the Rnd3 expression construct was described 
previously (Wennerberg et al., 2003). All cells were transfected using 
Lipofectamine 2000 (ThermoFisher Scientific) according to the man-
ufacturer’s protocol. Transfected cells were used for experiments 
24 h posttransfection.
siRNA
Two different siRNA duplexes targeting Rnd3 were used: Rnd3 #1 
(CUACA GUGUUUGAGAAUUAUU) and Rnd3 #2 (GCGGACAGAU-
GUUAGUACAUU) (Dharmacon). The nontargeting siControl#1 was 
also used (Dharmacon). The siRNAs were transfected into cells using 
Oligofectamine (Invitrogen) at a final concentration of 25 nM. After 
transfection, cells were cultured for an additional 72 h in complete 
medium, and then they were processed for further analysis.
RhoA activity assay
Cells were lysed for analysis of RhoA (10 mM MgCl2, 500 mM NaCl, 
50 mM Tris, pH 7.6, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate, 
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1 mM phenylmethylsulfonyl fluoride (PMSF), and 10 µg/ml aprotinin 
and leupeptin) and cleared at 14,000 ×  g for 5 min. Lysates were 
incubated with 50 µg of glutathione-Sepharose–bound glutathi-
one S-transferase (GST)-RBD (Rhotekin-binding domain) for 30 min 
at 4°C with gentle rocking. Beads were then washed three times in 
50 mM Tris, pH 7.6, 10 mM MgCl2, 150 mM NaCl, 1% Triton X-100, 
1 mM PMSF, and 10 µg/ml aprotinin and leupeptin. Released pro-
teins and reserved input control were subjected to Western blot 
analysis as described later.
GAP activity
Active RhoA GAPs were assayed using GST-RhoA Q63L as de-
scribed previously (Garcia Mata et al., 2006). Cells were lysed in 
150 mM NaCl, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid, pH 7.6, 10 mM MgCl2, 1% Triton X-100, 1 mM PMSF, and 
10 µg/ml aprotinin and leupeptin and incubated with 50 µg/ml glu-
tathione-Sepharose–bound GST-RhoAQ63L for 30 min at 4°C and 
washed in the lysis buffer. Samples were then analyzed by Western 
blotting as described later.
Immunoprecipitation and immunoblotting
For immunoprecipitation, cells were extracted on ice for 30 min in 
lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% 
Nonidet P-40, protease, and phosphatase inhibitors). After preclear-
ing with protein A/G-agarose beads, lysates were incubated with 
antibodies to p190 RhoGAP overnight at 4°C with rotation. Protein 
A/G agarose beads were added for the final hour of incubation. After 
being washed three times, the beads were resuspended in sample 
buffer, boiled for 10 min, and analyzed by Western blotting. For 
whole cell lysate analysis, cells were lysed in 2 × Laemmli sample buf-
fer and boiled for 5 min. For tissue blots, male C57BL/6 J mice were 
killed by CO2 inhalation and lung and testes were removed. Tissue 
was lysed in sample buffer by dounce homogenization. Animal ex-
periments were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina (IACUC-ID: 16-142). 
Samples were resolved on polyacrylamide gels in the presence of 
SDS. Resolved gels were transferred onto nitrocellulose membranes, 
blocked with 5% BSA in Tris-buffered saline (25 mM Tris, pH 7.6, 
150 mM NaCl) plus 0.1% Tween-20 (TBST) and incubated with pri-
mary antibody overnight at 4°C with gentle rocking. Blots were 
washed extensively in TBST before being incubated with species-
appropriate HRP-conjugated secondary antibody (Jackson Labora-
tories) for 1 h at room temperature. Blots were again washed in TBST, 
and fluorescence was detected using enhanced chemiluminescent 
reagent (ThermoFisher Scientific) and x-ray film.
Immunofluorescence
LL29 cells were plated onto fibronectin-coated coverslips for 24 h. In 
some experiments, cells were treated with pirfenidone (1 mM) or 
nintedanib 1 µM) for the final 16 h of plating before fixing/permea-
bilizing in 3.7% paraformaldehyde, then 0.02% Triton X-100. Texas 
Red phalloidin (Molecular Probes) was used to stain F-actin. Immu-
nofluorescence images were taken through a 20× objective (Zeiss 
plan-Apochromat 20x/0.8) with a Zeiss axiovert 200 M microscope 
equipped with a Hamamatsu ORCA-ERAG digital camera.
Conditioned medium
Confluent monolayers of cells were incubated in serum-free medium 
for 48 h to generate conditioned medium. The conditioned medium 
was then transferred to fresh plates of MRC5 cells for 24 h or ana-
lyzed for active TGF-β levels using a commercial ELISA (R&D Quan-
tikine ELISA Assay). In some experiments SB431452 (10 µM) was 
added to the conditioned medium. After 24 h the MRC5 cells were 
appropriately lysed for experiments as described.
Statistical analysis
Statistical differences between two groups of data were analyzed 
with a two-tailed unpaired Student’s t test. All graphical data are 
represented as a mean with data bars representing SEM.
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